Mentors

Prof. Thorpe is a statistician, educated at the University of Waterloo, with thirty years of experience with trials and studies spanning a wide range clinical fields including: cerebrovascular disease, nephrology, diabetes, cardiovascular disease, thrombosis, neonatology and oncology. His research interests include the design, conduct, data management and analysis of clinical trials, statistical education and statistical computing.  He was the lead author on the paper that first presented PRECIS, a tool to help trialists design their trials for pragmatic or explanatory purposes.

Prof. Thorpe is a statistician, educated at the University of Waterloo, with thirty years of experience with trials and studies spanning a wide range clinical fields including: cerebrovascular disease, nephrology, diabetes, cardiovascular disease, thrombosis, neonatology and oncology. His research interests include the design, conduct, data management and analysis of clinical trials, statistical education and statistical computing.  He was the lead author on the paper that first presented PRECIS, a tool to help trialists design their trials for pragmatic or explanatory purposes.

Dr. Mazer is a professor of Anesthesia and Physiology at the University of Toronto. His translational research program focuses on cardiovascular clinical trials, perioperative blood conservation, cardiac physiology and perioperative organ protection. He is also chair of the Research Ethics Board of Unity Health Toronto.

Dr. Mazer is a professor of Anesthesia and Physiology at the University of Toronto. His translational research program focuses on cardiovascular clinical trials, perioperative blood conservation, cardiac physiology and perioperative organ protection. He is also chair of the Research Ethics Board of Unity Health Toronto.

Dr. Anna Heath is a Scientist in the Child Health and Evaluative Sciences Program at SickKids Research Institute, an Assistant Professor in the Division of Biostatistics, University of Toronto and an Honorary Research Associate in the Department of Statistical Science, University College London, UK. She holds an MMath in Mathematics with French Language and a PhD in Statistical Science. Dr. Heath’s research focuses on developing new, innovative statistical methods to design, prioritise and analyse clinical research within a Bayesian framework. She is particularly interested in applying methods from decision theory, the science of determining the best course of action when the consequence of each action is uncertain, to the conception, design and analysis of clinical trials.

Dr. Anna Heath is a Scientist in the Child Health and Evaluative Sciences Program at SickKids Research Institute, an Assistant Professor in the Division of Biostatistics, University of Toronto and an Honorary Research Associate in the Department of Statistical Science, University College London, UK. She holds an MMath in Mathematics with French Language and a PhD in Statistical Science. Dr. Heath’s research focuses on developing new, innovative statistical methods to design, prioritise and analyse clinical research within a Bayesian framework. She is particularly interested in applying methods from decision theory, the science of determining the best course of action when the consequence of each action is uncertain, to the conception, design and analysis of clinical trials.

Dr. Ouyang is a Biostatistician in the Child Health and Evaluative Sciences Program at SickKids Research Institute, an Assistant Professor in the Division of Biostatistics, University of Toronto and an affiliate investigator at Ottawa Hospital Research Institute. He holds a PhD in Biostatistics and Epidemiology from the University of British Columbia, Vancouver, Canada. His research focuses on the design and analysis of clinical trials, with a particular emphasis on novel cluster randomized trials and Bayesian adaptive designs. His research also covers Quasi-experimental design and longitudinal data analysis. As a biostatistician, he actively collaborates with clinicians and researchers from various backgrounds and provides statistical consultations in study design, grant proposals, and data analysis.

Dr. Ouyang is a Biostatistician in the Child Health and Evaluative Sciences Program at SickKids Research Institute, an Assistant Professor in the Division of Biostatistics, University of Toronto and an affiliate investigator at Ottawa Hospital Research Institute. He holds a PhD in Biostatistics and Epidemiology from the University of British Columbia, Vancouver, Canada. His research focuses on the design and analysis of clinical trials, with a particular emphasis on novel cluster randomized trials and Bayesian adaptive designs. His research also covers Quasi-experimental design and longitudinal data analysis. As a biostatistician, he actively collaborates with clinicians and researchers from various backgrounds and provides statistical consultations in study design, grant proposals, and data analysis.

Associate Scientist of Paediatrics, Internal Medicine, Epidemiology & Biostatistics. Chair of Children’s Health Research Institute’s largest Division, Children’s Health and Therapeutics. Chair of Western University’s Health Sciences Research Ethics Board. ENRICH health research training platform executive board.

Associate Scientist of Paediatrics, Internal Medicine, Epidemiology & Biostatistics. Chair of Children’s Health Research Institute’s largest Division, Children’s Health and Therapeutics. Chair of Western University’s Health Sciences Research Ethics Board. ENRICH health research training platform executive board.

Monica Taljaard is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI) and Professor in the School of Epidemiology and Public Health at the University of Ottawa. Her main research interests are in the design, analysis and ethics of pragmatic and cluster randomized trials. As a methodologist with the Ottawa Methods Centre, she works with clinicians and researchers from a variety of backgrounds in the design and analysis of their studies including clinical trials and observational studies.

Monica Taljaard is a Senior Scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute (OHRI) and Professor in the School of Epidemiology and Public Health at the University of Ottawa. Her main research interests are in the design, analysis and ethics of pragmatic and cluster randomized trials. As a methodologist with the Ottawa Methods Centre, she works with clinicians and researchers from a variety of backgrounds in the design and analysis of their studies including clinical trials and observational studies.

Dr. Daniel McIsaac is an anesthesiologist and CIHR-funded scientist who combines expertise in data science and clinical trials to improve the outcomes of people having surgery. Primary focuses in Dr. McIsaac’s research include improving perioperative care for older people with frailty, assessing and improving health system performance through novel study design, and utilization of patient reported outcomes. Dr. McIsaac is currently leading or co-leading two national multicenter studies to improve postoperative outcomes using exercise prehabilitation (PREPARE Trial) and to better understand recovery trajectories after surgery in older people (FIT After Surgery Study).

Dr. Daniel McIsaac is an anesthesiologist and CIHR-funded scientist who combines expertise in data science and clinical trials to improve the outcomes of people having surgery. Primary focuses in Dr. McIsaac’s research include improving perioperative care for older people with frailty, assessing and improving health system performance through novel study design, and utilization of patient reported outcomes. Dr. McIsaac is currently leading or co-leading two national multicenter studies to improve postoperative outcomes using exercise prehabilitation (PREPARE Trial) and to better understand recovery trajectories after surgery in older people (FIT After Surgery Study).

Dr. Tim Ramsay has a PhD in biostatistics and is a Senior Scientist with the Clinical Epidemiology Program of the Ottawa Hospital Research Institute, as well as an Associate Professor with the University of Ottawa’s School of Epidemiology and Public Health.  He is Scientific Director of the Ottawa Methods Centre, a group of statisticians, information technology specialists, epidemiologists, and health-care economists that supports clinical research at The Ottawa Hospital and across Ontario through the CIHR-funded Strategy for Patient Oriented Research (SPOR).

Dr. Tim Ramsay has a PhD in biostatistics and is a Senior Scientist with the Clinical Epidemiology Program of the Ottawa Hospital Research Institute, as well as an Associate Professor with the University of Ottawa’s School of Epidemiology and Public Health.  He is Scientific Director of the Ottawa Methods Centre, a group of statisticians, information technology specialists, epidemiologists, and health-care economists that supports clinical research at The Ottawa Hospital and across Ontario through the CIHR-funded Strategy for Patient Oriented Research (SPOR).

Dr. Dean Fergusson is an established international leader in evidence-based transfusion medicine and clinical trial methods. Dr. Fergusson has conceived, designed, and conducted randomized trials in transfusion medicine that have advanced knowledge and practice in defining the optimal blood product to transfuse, establishing timelines to administer transfusions, and evaluating transfusion alternatives. Throughout his career, he has received over $263 million in peer reviewed research grants (including 156 CIHR grants), over $74.5 million as a principal investigator (including 43 CIHR grants), and major salary awards from CIHR and the Province of Ontario. He is one of the most cited and impactful researchers, having published over 664 peer-reviewed journal articles, many in high impact journals.

Dr. Dean Fergusson is an established international leader in evidence-based transfusion medicine and clinical trial methods. Dr. Fergusson has conceived, designed, and conducted randomized trials in transfusion medicine that have advanced knowledge and practice in defining the optimal blood product to transfuse, establishing timelines to administer transfusions, and evaluating transfusion alternatives. Throughout his career, he has received over $263 million in peer reviewed research grants (including 156 CIHR grants), over $74.5 million as a principal investigator (including 43 CIHR grants), and major salary awards from CIHR and the Province of Ontario. He is one of the most cited and impactful researchers, having published over 664 peer-reviewed journal articles, many in high impact journals.

Nick Barrowman is a PhD biostatistician with over 20 years of experience in the design and analysis of clinical studies. He is a Senior Statistician at the Clinical Research Unit of the CHEO RI and Associate Professor in the Department of Pediatrics at the University of Ottawa. He has published over 200 peer-reviewed papers in diverse fields and has also served as President of the Statistical Society of Ottawa and Statistical Consultant for the Canadian Medical Association Journal.

Nick Barrowman is a PhD biostatistician with over 20 years of experience in the design and analysis of clinical studies. He is a Senior Statistician at the Clinical Research Unit of the CHEO RI and Associate Professor in the Department of Pediatrics at the University of Ottawa. He has published over 200 peer-reviewed papers in diverse fields and has also served as President of the Statistical Society of Ottawa and Statistical Consultant for the Canadian Medical Association Journal.

I am a practicing pediatric emergency physician, hold a Tier I University of Ottawa Research Chair in Pediatric Emergency Medicine and am a Professor in the Departments of Pediatrics and Emergency Medicine at the University of Ottawa. My research focuses on the emergency department management of respiratory illnesses and musculoskeletal injuries, and patient safety. I have significant expertise in the conduct of multicenter randomized controlled trials and cohort studies.

I am a practicing pediatric emergency physician, hold a Tier I University of Ottawa Research Chair in Pediatric Emergency Medicine and am a Professor in the Departments of Pediatrics and Emergency Medicine at the University of Ottawa. My research focuses on the emergency department management of respiratory illnesses and musculoskeletal injuries, and patient safety. I have significant expertise in the conduct of multicenter randomized controlled trials and cohort studies.

Dr. Wells is a Professor in the School of Epidemiology and Public Health at the University of Ottawa and Director of the Cardiovascular Research Methods Centre at the University of Ottawa Heart Institute. He is also a Professor in the Department of Medicine at the University of Ottawa.

Dr. Wells is a Professor in the School of Epidemiology and Public Health at the University of Ottawa and Director of the Cardiovascular Research Methods Centre at the University of Ottawa Heart Institute. He is also a Professor in the Department of Medicine at the University of Ottawa.

Dr. Hazlewood is an Associate Professor of Medicine in the Cumming School of Medicine at the University of Calgary, and a practicing rheumatologist. He is a member of the McCaig Institute for Bone and Joint Health, Arthritis Research Canada and chairs the Guidelines Committee through the Canadian Rheumatology Association.

Dr. Hazlewood is an Associate Professor of Medicine in the Cumming School of Medicine at the University of Calgary, and a practicing rheumatologist. He is a member of the McCaig Institute for Bone and Joint Health, Arthritis Research Canada and chairs the Guidelines Committee through the Canadian Rheumatology Association.

Stephanie Dixon is an ICES Scientist in the Kidney, Dialysis and Transplantation program at London Health Sciences Centre (LHSC) and an Adjunct Research Associate Professor, Department of Epidemiology and Biostatistics, Western University. Her main research interest is the design and analysis of pragmatic and cluster randomized trials with a focus on outcomes obtained from routinely collected data. She collaborates closely with nephrologists and policy makers from the Ontario Renal Network (the agency responsible for delivery of chronic kidney disease services in Ontario) for clinical trials, observational research and multi-jurisdictional work.

Stephanie Dixon is an ICES Scientist in the Kidney, Dialysis and Transplantation program at London Health Sciences Centre (LHSC) and an Adjunct Research Associate Professor, Department of Epidemiology and Biostatistics, Western University. Her main research interest is the design and analysis of pragmatic and cluster randomized trials with a focus on outcomes obtained from routinely collected data. She collaborates closely with nephrologists and policy makers from the Ontario Renal Network (the agency responsible for delivery of chronic kidney disease services in Ontario) for clinical trials, observational research and multi-jurisdictional work.

Practices nephrology at the London Health Sciences Centre, where he provides care and conducts research to improve health outcomes for patients with kidney disease including those receiving dialysis or a kidney transplant.

Leadership positions include Associate Dean, Clinical Research, Schulich School of Medicine and Dentistry, Lead, ICES Kidney, Dialysis and Transplantation Provincial Programs. A Past President of the Canadian Society of Nephrology, and a Past Provincial Medical Lead for the Ontario Renal Network dedicated to improving access to kidney transplantation and living kidney donation.

Professor of Medicine, Epidemiology and Biostatistics at Western University. Productive investigator (over 650 publications, h-index 113). A current focus is the conduct of pragmatic randomized trials embedded into routine healthcare delivery.

Practices nephrology at the London Health Sciences Centre, where he provides care and conducts research to improve health outcomes for patients with kidney disease including those receiving dialysis or a kidney transplant.

Leadership positions include Associate Dean, Clinical Research, Schulich School of Medicine and Dentistry, Lead, ICES Kidney, Dialysis and Transplantation Provincial Programs. A Past President of the Canadian Society of Nephrology, and a Past Provincial Medical Lead for the Ontario Renal Network dedicated to improving access to kidney transplantation and living kidney donation.

Professor of Medicine, Epidemiology and Biostatistics at Western University. Productive investigator (over 650 publications, h-index 113). A current focus is the conduct of pragmatic randomized trials embedded into routine healthcare delivery.

Dr. Tu is a Senior Biostatistician/Data Scientist in the Canadian Cancer Trials Group at the Queen’s Cancer Research Institute and an Assistant Professor in the Department of Public Health Sciences. Dr. Tu’s research lies in the intersection of health science and the emerging data science. With the advancement of digital technologies, different sources of data (genetic, imaging, electronic health records, etc.) are available in health science. Trained as a biostatistician, Dr. Tu is interested in integrating these different sources of high-dimensional data and translate into informed clinical decision-making.

Dr. Tu is a Senior Biostatistician/Data Scientist in the Canadian Cancer Trials Group at the Queen’s Cancer Research Institute and an Assistant Professor in the Department of Public Health Sciences. Dr. Tu’s research lies in the intersection of health science and the emerging data science. With the advancement of digital technologies, different sources of data (genetic, imaging, electronic health records, etc.) are available in health science. Trained as a biostatistician, Dr. Tu is interested in integrating these different sources of high-dimensional data and translate into informed clinical decision-making.

Dr. Wendy Parulekar is a graduate of the University of Ottawa where she completed her medical school and specialty training in Internal Medicine and Medical Oncology followed by postgraduate training in clinical pharmacology at the University of Toronto. She currently holds a joint research/clinical position at Queen’s University Cancer Research Institute as a Professor of Oncology and Senior Investigator at the Canadian Cancer Trials Group and Medical Oncologist at the Cancer Centre of Southeastern Ontario. She advises on the clinical trial research agenda for multiple national and international committees including the National Cancer Research Institute (NCRI): International Clinical Trials Awards and Advisory Panel, the European Organization for Research and Treatment of Cancer, Steering Committees for the NCI US, Canadian Institutes of Health Research and the Ontario Institute of Cancer Research.

Dr. Wendy Parulekar is a graduate of the University of Ottawa where she completed her medical school and specialty training in Internal Medicine and Medical Oncology followed by postgraduate training in clinical pharmacology at the University of Toronto. She currently holds a joint research/clinical position at Queen’s University Cancer Research Institute as a Professor of Oncology and Senior Investigator at the Canadian Cancer Trials Group and Medical Oncologist at the Cancer Centre of Southeastern Ontario. She advises on the clinical trial research agenda for multiple national and international committees including the National Cancer Research Institute (NCRI): International Clinical Trials Awards and Advisory Panel, the European Organization for Research and Treatment of Cancer, Steering Committees for the NCI US, Canadian Institutes of Health Research and the Ontario Institute of Cancer Research.

Shirin Golchi is an assistant professor of biostatistics at the Department of Epidemiology and Biostatistics, McGill University. Her research interests are Bayesian modelling and computation with a focus on Bayesian adaptive clinical trials. She graduated from Simon Fraser University with a PhD in statistics in 2014. Before coming to McGill she worked as a senior statistician at MTEK Sciences, a health research company which was later acquired by Cytel.

Shirin Golchi is an assistant professor of biostatistics at the Department of Epidemiology and Biostatistics, McGill University. Her research interests are Bayesian modelling and computation with a focus on Bayesian adaptive clinical trials. She graduated from Simon Fraser University with a PhD in statistics in 2014. Before coming to McGill she worked as a senior statistician at MTEK Sciences, a health research company which was later acquired by Cytel.

Dr. Hudson is a rheumatologist and clinician-scientist at the Jewish General Hospital and Lady Davis Institute, and an Associate professor and Member of the Division of Experimental Medicine in the Department of Medicine at McGill University. She pursues research in systemic autoimmune rheumatic diseases, including a feasibility study for an adaptive trial for rheumatoid arthritis and a Phase I/II Bayesian adaptive trial of umbilical cord-derived mesenchymal stromal cells in systemic sclerosis. Dr Hudson is also Co-Director of the McGill Interdisciplinary Initiative in Infection and Immunity which, since 2018, has provided over $34 million to support 130+ innovative research projects.

Dr. Hudson is a rheumatologist and clinician-scientist at the Jewish General Hospital and Lady Davis Institute, and an Associate professor and Member of the Division of Experimental Medicine in the Department of Medicine at McGill University. She pursues research in systemic autoimmune rheumatic diseases, including a feasibility study for an adaptive trial for rheumatoid arthritis and a Phase I/II Bayesian adaptive trial of umbilical cord-derived mesenchymal stromal cells in systemic sclerosis. Dr Hudson is also Co-Director of the McGill Interdisciplinary Initiative in Infection and Immunity which, since 2018, has provided over $34 million to support 130+ innovative research projects.

I am a professor in biostatistics in Faculty of Medicine at Memorial University of Newfoundland. My research focuses on innovative design of clinical trials and statistical inference. I have over ten years of experience in adaptive randomization for clinical trials.

I am a professor in biostatistics in Faculty of Medicine at Memorial University of Newfoundland. My research focuses on innovative design of clinical trials and statistical inference. I have over ten years of experience in adaptive randomization for clinical trials.

Dr. Rash an Associate Professor in the Dept. of Psychology at Memorial University of Newfoundland, Director of the Memorial University of Newfoundland – Behavioural Medicine Centre (MUN-BMC), and Senior Research Fellow at the Duke University Center for Health Policy and Inequalities Research (CHPIR). He has significant experience conducting multi-site, pragmatic clinical trials that involve pharmacological and behavioural interventions. His expertise is highly sought out in chronic pain management, weight management, stress management, motivating health behaviour change, treatment of insomnia, and cardiovascular psychophysiology.

Dr. Rash an Associate Professor in the Dept. of Psychology at Memorial University of Newfoundland, Director of the Memorial University of Newfoundland – Behavioural Medicine Centre (MUN-BMC), and Senior Research Fellow at the Duke University Center for Health Policy and Inequalities Research (CHPIR). He has significant experience conducting multi-site, pragmatic clinical trials that involve pharmacological and behavioural interventions. His expertise is highly sought out in chronic pain management, weight management, stress management, motivating health behaviour change, treatment of insomnia, and cardiovascular psychophysiology.

Dr Tolu Sajobi is an Associate Professor of Biostatistics in the Departments of Community Health Sciences and Clinical Neurosciences at the University of Calgary. His research program focuses on measurement and analysis of patient-reported outcomes, design and analysis of clinical trials, and development and implementation of clinical decision aids.

Dr Tolu Sajobi is an Associate Professor of Biostatistics in the Departments of Community Health Sciences and Clinical Neurosciences at the University of Calgary. His research program focuses on measurement and analysis of patient-reported outcomes, design and analysis of clinical trials, and development and implementation of clinical decision aids.

Stroke neurologist and clinical trialist with interests in neuro-epidemiology and advancing therapeutics in stroke and neurology.  I also have a role in the province as medical lead for cardiovascular and stroke.

Stroke neurologist and clinical trialist with interests in neuro-epidemiology and advancing therapeutics in stroke and neurology.  I also have a role in the province as medical lead for cardiovascular and stroke.

Robert Balshaw’s interests include innovative trials design, causal inference in observational studies, methods for biomarker discovery, refinement and validation. He is becoming very curious about the Bayesian approach to scientific thinking.

Robert Balshaw’s interests include innovative trials design, causal inference in observational studies, methods for biomarker discovery, refinement and validation. He is becoming very curious about the Bayesian approach to scientific thinking.

Dr. Kelly is an Assistant Professor in the department of pharmacology and therapeutics at the University of Manitoba, director of clinical trials at the Children’s Hospital Research Institute of Manitoba and Principal Investigator for the clinical pharmacology lab. Dr. Kelly is a certified clinical research professional who leads several clinical trials on cannabinoid therapeutics as the scientific director for the Canadian Collaborative for Childhood Cannabinoid Therapeutics (C4T). She also provides methods expertise and training in clinical trials for researchers across Manitoba in her role as a Clinical Trialist at the George and Fay Yee Centre for Healthcare Innovation. Dr. Kelly is a consultant with the Conect4Children pan-European clinical trials network and KidsCan Trials within the Maternal Infant Child Youth Research Network.

Dr. Kelly is an Assistant Professor in the department of pharmacology and therapeutics at the University of Manitoba, director of clinical trials at the Children’s Hospital Research Institute of Manitoba and Principal Investigator for the clinical pharmacology lab. Dr. Kelly is a certified clinical research professional who leads several clinical trials on cannabinoid therapeutics as the scientific director for the Canadian Collaborative for Childhood Cannabinoid Therapeutics (C4T). She also provides methods expertise and training in clinical trials for researchers across Manitoba in her role as a Clinical Trialist at the George and Fay Yee Centre for Healthcare Innovation. Dr. Kelly is a consultant with the Conect4Children pan-European clinical trials network and KidsCan Trials within the Maternal Infant Child Youth Research Network.

Joel Singer is a professor in the School of Population and Public Health at UBC. He has been involved as a clinical trials methodologist and analyst since the 1980s and has been methodological lead on many national and international trials in diverse clinical areas including HIV, COVID, cardiology, nephrology and health behaviours. He has been a member and chair of many Data Safety Monitoring Boards.

Joel Singer is a professor in the School of Population and Public Health at UBC. He has been involved as a clinical trials methodologist and analyst since the 1980s and has been methodological lead on many national and international trials in diverse clinical areas including HIV, COVID, cardiology, nephrology and health behaviours. He has been a member and chair of many Data Safety Monitoring Boards.

Dr. Russell’s major current themes of research are (1) randomized controlled trials in patients with septic shock and now COVID-19 and (2) biomarkers of septic shock and COVID-19.

• The COVID-19 pandemic led to success to study acute and long COVID-19 with 4 Canadian Institutes of Health Research (CIHR) grants and 3 St. Paul’s Foundation grants totalling $4.3 M and 18 peer-reviewed publications (details below).
• Finding and validating new therapies in sepsis and septic shock has been difficult. Dr. Russell is enunciating a new tripartite strategy to increase the yield of breakthrough therapies in sepsis and septic shock by using (1) predictive biomarkers in trials with (2) response adaptive trial design and (3) focus on short-term organ dysfunction primary endpoints.

Dr. Russell’s major current themes of research are (1) randomized controlled trials in patients with septic shock and now COVID-19 and (2) biomarkers of septic shock and COVID-19.

• The COVID-19 pandemic led to success to study acute and long COVID-19 with 4 Canadian Institutes of Health Research (CIHR) grants and 3 St. Paul’s Foundation grants totalling $4.3 M and 18 peer-reviewed publications (details below).
• Finding and validating new therapies in sepsis and septic shock has been difficult. Dr. Russell is enunciating a new tripartite strategy to increase the yield of breakthrough therapies in sepsis and septic shock by using (1) predictive biomarkers in trials with (2) response adaptive trial design and (3) focus on short-term organ dysfunction primary endpoints.

I have been involved in clinical trials for more than 20 years across diverse medical areas including mental health, HIV, emergency medicine, neurology, women & children’s health, and rehabilitation medicine. My methodological research interests are in the design of pragmatic clinical trials, with a current focus on the embedding of trials within learning health systems to support personalized treatment decisions.

I have been involved in clinical trials for more than 20 years across diverse medical areas including mental health, HIV, emergency medicine, neurology, women & children’s health, and rehabilitation medicine. My methodological research interests are in the design of pragmatic clinical trials, with a current focus on the embedding of trials within learning health systems to support personalized treatment decisions.

Dr. Fidel Vila-Rodriguez is an assistant professor in the Department of Psychiatry at the University of British Columbia and director of the Non-Invasive Neurostimulation Therapies (NINET) Laboratory and Schizophrenia Program. He is also a Michael Smith Foundation for Health Research Scholar.

As a clinician-scientist, he has a strong interest in conducting translational research that bridges the neurobiology of psychiatric disorders with the clinical applications of this knowledge. His clinical practice is actively focused in those most severely afflicted by such conditions, and his research interests are directed at finding novel therapeutic interventions within NINET that can help mitigate the suffering of those with severe and refractory forms of psychosis and depression. His laboratory actively investigates on all forms of NINET and uses a varied number of neurophysiological tools to research on biomarkers. The NINET Laboratory is the only centre in Canada to host both simultaneous TMS-fMRI and tDCS-fMRI capability.

Dr. Fidel Vila-Rodriguez is an assistant professor in the Department of Psychiatry at the University of British Columbia and director of the Non-Invasive Neurostimulation Therapies (NINET) Laboratory and Schizophrenia Program. He is also a Michael Smith Foundation for Health Research Scholar.

As a clinician-scientist, he has a strong interest in conducting translational research that bridges the neurobiology of psychiatric disorders with the clinical applications of this knowledge. His clinical practice is actively focused in those most severely afflicted by such conditions, and his research interests are directed at finding novel therapeutic interventions within NINET that can help mitigate the suffering of those with severe and refractory forms of psychosis and depression. His laboratory actively investigates on all forms of NINET and uses a varied number of neurophysiological tools to research on biomarkers. The NINET Laboratory is the only centre in Canada to host both simultaneous TMS-fMRI and tDCS-fMRI capability.

I have been involved in clinical trials for more than 20 years across diverse medical areas including mental health, HIV, emergency medicine, neurology, women & children’s health, and rehabilitation medicine. My methodological research interests are in the design of pragmatic clinical trials, with a current focus on the embedding of trials within learning health systems to support personalized treatment decisions.

I have been involved in clinical trials for more than 20 years across diverse medical areas including mental health, HIV, emergency medicine, neurology, women & children’s health, and rehabilitation medicine. My methodological research interests are in the design of pragmatic clinical trials, with a current focus on the embedding of trials within learning health systems to support personalized treatment decisions.

Dr Hawkins is a clinician-scientist cardiologist and Associate Professor at UBC with dual training in heart failure and electrophysiology. His leadership roles include Medical Lead for Quality and Research at Cardiac Services BC, and Director of Research for the UBC Division of Cardiology. His research group examines cardiovascular outcomes, health services, and comorbidities in patients with heart failure, arrhythmia, and pulmonary disease. He is Co-PI for the MAPLE-CHF and international SYMPHONY heart failure screening trial, member of the CIHR Canadian Heart Function Alliance, and Co-PI for the Canadian Cardiovascular Society MYCOVACC national surveillance study of myocarditis and/or pericarditis following mRNA COVID-19 vaccination.

Dr Hawkins is a clinician-scientist cardiologist and Associate Professor at UBC with dual training in heart failure and electrophysiology. His leadership roles include Medical Lead for Quality and Research at Cardiac Services BC, and Director of Research for the UBC Division of Cardiology. His research group examines cardiovascular outcomes, health services, and comorbidities in patients with heart failure, arrhythmia, and pulmonary disease. He is Co-PI for the MAPLE-CHF and international SYMPHONY heart failure screening trial, member of the CIHR Canadian Heart Function Alliance, and Co-PI for the Canadian Cardiovascular Society MYCOVACC national surveillance study of myocarditis and/or pericarditis following mRNA COVID-19 vaccination.